Breakthrough Therapy Offers Fertility Hope for Endometrial Cancer Patients

Endometrial cancer poses a significant health risk, especially for younger women who wish to preserve fertility. Standard treatment often involves hysterectomy, which permanently ends reproductive ability. Researchers have now developed a new approach to identify and treat patients resistant to hormone therapy. A research team created a patient-derived tumour cell cluster model that mirrors the key features of endometrioid endometrial carcinoma (EEC). Using hyperspectral stimulated Raman scattering microscopy, they observed abnormal cholesterol ester accumulation in progesterone-insensitive tumours. This build-up acts as a molecular signature, predicting resistance to progestin therapy.

The team found that cholesterol ester percentage (CEP) could distinguish between progesterone-sensitive and insensitive patients. It also helped monitor treatment progress over time. Further investigation revealed that cholesterol esters indicate metabolic changes in tumours, which may reduce the effectiveness of hormone therapy.

Combining progestin with a statin disrupted this metabolic adaptation. The new therapy achieved a six-month complete remission rate of 66.67% in progesterone-insensitive patients. This was a sharp increase from the 7.69% remission rate seen with progestin alone. One patient even gave birth to a healthy child after the combined treatment, marking the first successful 'statin baby' in EEC care. The findings offer a new way to identify and treat progesterone-insensitive patients. The statin-progestin combination shows promise in improving remission rates while preserving fertility. This could change how clinicians manage EEC in women hoping to have children.